Iovance unleashes natural-born killers: tumor-infiltrating lymphocytes

Applying its TIL-based therapy, Iovance Biotherapeutics is expanding TIL numbers in patients to target solid tumors.

Like Comment
Page of
Go to the profile of Iovance Biotherapeutics

Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer.

No comments yet.